Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics Granted US Patent for Proprietary Therapeutic Delivery Platform, Strengthening Company’s Intellectual Property Position in Immunotherapy
LA JOLLA, Calif., [May 24, 2022] — Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering…
Calidi Biotherapeutics Announces Appointment of Alfonso “Chito” Zulueta, Former President of International for Eli Lilly, to Its Board of Directors
LA JOLLA, Calif.–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc., a Nevada corporation (“Calidi”), is a clinical-stage biotechnology company…
Calidi Biotherapeutics and Edoc Acquisition Corp. Agree to Merge and Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
-Total gross proceeds from transaction expected to be approximately $117 million prior to redemptions, combining…
Calidi Biotherapeutics Announces Dr. Maciej S. Lesniak Presentation at 13th International Oncolytic Virotherapy Conference
LA JOLLA, Calif.–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem…
Calidi Biotherapeutics Announces Presentation at 6th Annual Oncolytic Virotherapy Summit
LA JOLLA, Calif.–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem…
Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago for Novel Oncolytic Virotherapy Technology
LA JOLLA, Calif.–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company with novel allogeneic stem cell…